Biotechnology News and Research

RSS

DIATHERIX Laboratories granted EUA for H1N1-09 Influenza Test

DIATHERIX Laboratories, Inc. is pleased to announce it has been granted emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its DIATHERIX H1N1-09 Influenza Test.

14 Oct 2009

Preliminary results of its tender offer announced by Cardiome Pharma

Cardiome Pharma Corp. announced the preliminary results of its modified "Dutch Auction" tender offer to purchase for cancellation up to US$27.5 million of its common shares (the "Offer"), which expired at 5:00 p.m. (Eastern time) on October 13, 2009.

14 Oct 2009

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

Integrated Diagnostics launched officially today with more than $30 million in funding. A pre-eminent team of scientists and investors are behind the company, which was founded by renowned biotechnology innovator Dr. Leroy Hood. Integrated Diagnostics will focus on developing personalized and preventive diagnostics based on breakthroughs using genomic and proteomic technologies to identify organ-specific proteins.

14 Oct 2009

BioMedReports electronic newsletter releases an article about Biomagnetics Diagnostics

Biomagnetics Diagnostics Corp., a producer of revolutionary diagnostic systems and technology for malaria, tuberculosis, HIV, and hepatitis testing, today announced the Company is the subject of a cover page story in the prestigious BioMedReports electronic newsletter and portal.

14 Oct 2009

Results of tender offer announced by Elan Corporation

Elan Corporation, plc today announced the results as of the early tender date of the tender offer for the 7¾% Senior Fixed Rate Notes due 2011 (CUSIP No. 284138AC8) (the “Notes”) issued by its wholly-owned subsidiaries, Elan Finance public limited company and Elan Finance Corp. (the “Co-Issuers”).

14 Oct 2009

Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine

Nobilon, the human vaccine business unit of Schering-Plough Corporation (NYSE: SGP), today announced that it has initiated a clinical Proof of Concept trial with SCH 900795, a new intranasal Live Attenuated Influenza Vaccine (LAIV) for annual seasonal use.

14 Oct 2009

Senate Finance Committee's bipartisan bill is the best blueprint for comprehensive health care reform: PhRMA

"Today's vote represents an important step forward for the millions of Americans who don't have access to high-quality and affordable health care coverage and services. Chairman Baucus has tirelessly shepherded one of the most important pieces of legislation in our lifetime and deserves a lot of credit for reaching out to members on both sides of the aisle.

14 Oct 2009

Fraunhofer CSE opens new PV module laboratory

This afternoon, Fraunhofer USA, Inc.'s Center for Sustainable Energy Systems (CSE) officially opened its first laboratory, a PV module innovation facility at a high-profile ribbon-cutting ceremony headlined by German Ambassador Klaus Scharioth and Massachusetts Energy Secretary Bowles.

14 Oct 2009

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

VIA Pharmaceuticals, Inc., a biotechnology company focused on the development of compounds for the treatment of cardiovascular and metabolic disease, today announced that on October 9, 2009, it received a determination letter from The NASDAQ Stock Market notifying the Company that the NASDAQ Hearing Panel (the "Panel") has granted the Company's request to remain listed on NASDAQ, subject to the Company demonstrating compliance with the NASDAQ Listing Rules (the "Listing Rules") on or before December 31, 2009 (the "Exception Period").

14 Oct 2009

International Stem Cell launches human cell culture products into commercial research markets

International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs.

14 Oct 2009

Research reveals the genetic basis of DispersinB enzyme substrate based biofilm formation in bacteria

Kane Biotech Inc., a biotechnology company engaged in the development of products that prevent and disperse bacterial biofilms is pleased to announce that a recent research publication from Princeton University reveals the genetic basis of poly-ß-1,6-N-acetylglucosamine (PNAG), the DispersinB® enzyme substrate, based biofilm formation in bacteria.

14 Oct 2009

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

In September 2009, the Kansas City District Office of the Food and Drug Administration (FDA) submitted a recommendation of approval to the Center for Drug Evaluation and Research for The University of Iowa Pharmaceuticals (UIP) to manufacture and test an aseptically filled, sterile prescription drug product for a commercial client. The drug product contains a new chemical entity and is a sterile solution that is aseptically filled into vials.

14 Oct 2009

New generation of forensic DNA kits to provide faster DNA results

Applied Biosystems, part of Life Technologies Corporation, today announced a new generation of forensic DNA kits with chemistry reagents designed to address the increasing challenges facing 21st century forensic laboratories.

14 Oct 2009

Sosei Group assigns its SD281 drug discovery programme to Biocopea

Sosei Group Corporation, a biopharmaceutical company, today announces the assignment of the drug discovery programme, SD281 and its analogues, to Biocopea Limited, a UK biotechnology company and subsidiary of PepTcell Limited. These compounds, based on a metabolite of a well-known drug, were shown by Sosei to have pronounced anti-inflammatory properties.

14 Oct 2009

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

Champions Biotechnology, Inc., a drug development company with a preclinical platform able to predict clinical effectiveness, accelerate development and enhance the value of oncology drugs, today announced that the United States Patent and Trademark Office issued a patent on September 29, 2009 for the company's tubulin inhibitors, including its lead compound SG410.

14 Oct 2009

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

Novavax, Inc. announced today that it has received a Small Business and Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant from the NIAID is to support a segment of the Company's preclinical research program for the respiratory syncytial virus (RSV) particle-based vaccine.

14 Oct 2009

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Metabolic Solutions Development Company (MSDC) announced today that it has received a $100,000 grant from the Alzheimer's Drug Discovery Foundation (ADDF) to support the evaluation of PPAR-sparing insulin sensitizers as a potential treatment for Alzheimer's disease.

14 Oct 2009

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

BioMimetic Therapeutics, Inc. today announced positive top-line results from its North American pivotal (Phase III) randomized controlled trial comparing its fully synthetic, off-the-shelf bone growth factor product, Augment Bone Graft (“Augment”), to autograft for use in hindfoot and ankle fusion surgery.

14 Oct 2009

Positive results from Alkermes' ALKS 33 clinical trials announced

Alkermes, Inc. today announced positive topline data from two clinical trials of ALKS 33, an investigational oral opioid modulator for the treatment of addiction and other central nervous system disorders. Data from the studies, ALK33-003 and ALK33-004, showed that ALKS 33 was generally well tolerated and successfully blocked the effects of an opioid, with a duration of action that supports once daily dosing.

13 Oct 2009

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Dyax Corp. announced today new developments involving drug candidates identified using the Company’s proprietary phage display technology as a result of two deals recently announced by sanofi-aventis.

13 Oct 2009

Biotechnology News and Research

DIATHERIX Laboratories granted EUA for H1N1-09 Influenza Test

Preliminary results of its tender offer announced by Cardiome Pharma

Integrated Diagnostics launched to develop diagnostic tools and innovative biomarkers

BioMedReports electronic newsletter releases an article about Biomagnetics Diagnostics

Results of tender offer announced by Elan Corporation

Nobilon initiates a clinical Proof of Concept trial with SCH 900795 vaccine

Senate Finance Committee's bipartisan bill is the best blueprint for comprehensive health care reform: PhRMA

Fraunhofer CSE opens new PV module laboratory

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

International Stem Cell launches human cell culture products into commercial research markets

Research reveals the genetic basis of DispersinB enzyme substrate based biofilm formation in bacteria

FDA recommends approval for UI Pharmaceuticals to manufacture an aseptically filled sterile drug product

New generation of forensic DNA kits to provide faster DNA results

Sosei Group assigns its SD281 drug discovery programme to Biocopea

Champions Biotechnology receives U.S. patent for its tubulin inhibitors

NIH awards Novavax a SBIR grant for respiratory syncytial virus vaccine research

ADDF grant to support the evaluation of PPAR-sparing insulin sensitizers

Positive results from BioMimetic Therapeutics' Phase III trial comparing Augment Bone Graft to autograft

Positive results from Alkermes' ALKS 33 clinical trials announced

Sanofi-aventis collaborates with Merrimack Pharmaceuticals for rights to human monoclonal antibody MM-121

Biotechnology eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News